viewRedHill Biopharma

Redhill Biopharma's Opaganib 'one of most advanced, novel investigational drugs for Covid-19'

RedHill Biopharma Ltd's (Nasdaq: RDHL) Guy Goldberg talks to Proactive London about their operations, which include working towards a remedy for Covid-19 with Opaganib.

Goldberg describes the drug as 'one of most advantaged, novel investigational Covid-19 drugs'. Opaganib is orally-taken, which targets a host cell component and is unaffected by viral mutation.

Goldberg explains why the drug is unique with its 'mechanism for action', first being that it is anti-viral and secondly, that it is anti-inflammatory'.

The medicine is already available in Israel on a 'compassionate' use basis, which has proved successful for five patients who had 'moderate to severe' Covid-19 symptoms.

Quick facts: RedHill Biopharma

Price: 7.83 USD

Market: NASDAQ
Market Cap: $329.02 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of RedHill Biopharma named herein, including the promotion by the Company of RedHill Biopharma in any Content on the Site, the Company receives...


Metal Tiger on Kitlanya East copper-silver project progress and oncoming...

Metal Tiger PLC's (LON:MTR) Michael McNeilly catches up with Proactive London's Katie Pilbeam after reporting progress at the Kitlanya East copper-silver project in Botswana, operated by Kalahari Metals Ltd (KML). McNeilly explains the potential for the South Fold target to host copper-silver...

1 day, 7 hours ago

2 min read